<DOC>
	<DOCNO>NCT02436889</DOCNO>
	<brief_summary>An 8-week randomized , control , pilot clinical trial Mirabegron compare standard anticholinergic therapy ( Detrol LA ) elderly woman urgency urinary incontinence .</brief_summary>
	<brief_title>Treatment Incontinence Without Memory Problems</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Urge</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Communitydwelling , ambulatory female ≥ 65 year old Urgency Mixed Urgency Predominate Urinary Incontinence ( subjectreported ) ≥ 3 month prior Screening ( Visit 1 ) On 3day void diary , documentation least 3 urgency incontinence episode number urgency incontinence episode great number stress incontinence episode Capability understanding sign informed consent form full discussion research nature treatment risk benefit Ability perform procedure test require protocol Report primary health care provider Willingness remain stable medication regime duration randomize control trial . Participants ask add new medication randomize controlled trial , diuretic medication may affect void pattern . Seated blood pressure &gt; 180/110 Screening Baseline Physician diagnosis dementia Current use dementia medication , debilitate recent neurologic disease Mini Mental State Examination ( MMSE ) score &lt; 20 History urinary retention , gastric retention , uncontrolled narrow angle glaucoma , myasthenia gravis , severe ulcerative colitis , toxic megacolon , fistula hole bladder rectum , birth defect lead urine leakage , urine leakage start childhood Clinically significant hepatic ( Child Pugh B great ) renal ( creatinin clearance &lt; 30 mL/min eGFR &lt; 30 mL/min/1.73 m2 ) Neurologic condition stroke , multiple sclerosis , spinal cord injury , Parkinson 's disease . Major cardiovascular even past 6 month ( i.e. , MI , unstable angina , hospitalization chest pain ) Symptomatic pelvic organ prolapse define participant report feel see bulge outside vagina within past 3 month . History surgery incontinence past 5 year , pelvic surgery past 6 month ( i.e. , prolapse hysterectomy ) , intravesical therapy ( botox ) , and/or bulk injection within past 6 month . A known history interstitial cystitis significant pain component associate OAB symptom , uninvestigated hematuria , urogenital cancer , radiation pelvis external genitalia . Urinary tract infection ( UTI ) show result urinalysis screening recurrent urinary tract infection ( RUTIs ) define treatment UTI &gt; 3 time last year . Urinary retention ( postvoid residual urine volume &gt; 150 cc measure Bladder scan screening . Use electrostimulation , bladder training , pelvic floor exercise ( certify incontinence practitioner ) within 4 week Screening . Received study medication previous mirabegron clinical trial . Prior failure either efficacy tolerability ≥ 2 OAB medication last year . ( Failure : inadequate symptom control two medication minimum one month . ) Has treat within 2 week prior Screening and/or currently treat : Any drug treatment OAB Any drug significant anticholinergic antispasmodic effect ( see exception tricyclic antidepressant ) Has start treatment tricyclic antidepressant estrogens within 4 week prior Screening and/or stable dose . Intermittent use unstable dose diuretic . Treatment diuretic initiate within 2 week prior baseline and/or stable dose permit . Treatment potent CYP3A4 inhibitor , clarithromycin , ketoconazole , itraconazole within 2 week prior Screening . Administration medication capable induce hepatic enzyme metabolism transport ( e.g. , barbiturate , rifampicin , carbamazepine , phenytoin , primidone , St. John 's Wort ) past 30 day . Administration narrow therapeutic index drug metabolize CYP2D6 , thioridazine , flecainide , propafenone . Previously receive investigational drug within 30 day prior trial entry . Alcohol and/or drug abuse opinion investigator . Participants medical ( include know history major hematological , renal , cardiovascular , hepatic abnormality ) psychological condition social circumstance would impair ability participate reliably trial , may increase risk others participate . Participants , opinion investigator , likely complete trial whatever reason .</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>